Patent: 8,420,089
✉ Email this page to a colleague
Summary for Patent: 8,420,089
| Title: | Antagonists of IL-6 to raise albumin and/or lower CRP |
| Abstract: | The present invention is directed to therapeutic methods using IL-6 antagonists such as antibodies and fragments thereof having binding specificity for IL-6 to improve survivability or quality of life of a patient in need thereof. In preferred embodiments, the anti-IL-6 antibodies will be humanized and/or will be aglycosylated. Also, in preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level or a reduced serum albumin level prior to treatment. In another preferred embodiment, the patient\'s Glasgow Prognostic Score will be increased and survivability will preferably be improved. |
| Inventor(s): | Smith; Jeffrey T. L. (Redmond, WA) |
| Assignee: | AlderBio Holdings LLC (Las Vegas, NV) |
| Application Number: | 12/624,965 |
| Patent Claims: | see list of patent claims |
Details for Patent 8,420,089
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | ARZERRA | ofatumumab | Injection | 125326 | 10/26/2009 | ⤷ Try a Trial | 2028-11-25 |
| Novartis Pharmaceuticals Corporation | ARZERRA | ofatumumab | Injection | 125326 | 04/01/2011 | ⤷ Try a Trial | 2028-11-25 |
| Novartis Pharmaceuticals Corporation | KESIMPTA | ofatumumab | Injection | 125326 | 08/20/2020 | ⤷ Try a Trial | 2028-11-25 |
| Genentech, Inc. | PERJETA | pertuzumab | Injection | 125409 | 06/08/2012 | ⤷ Try a Trial | 2028-11-25 |
| Genentech, Inc. | OCREVUS | ocrelizumab | Injection | 761053 | 03/28/2017 | ⤷ Try a Trial | 2028-11-25 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
